Skip to main content
Retour
CRON logo

Cronos Group Inc.

Qualité des données : 100%
CRON
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
2,62 €
▲ 0,04 € (1,55%)
Cap. Boursière : 1,01B
Fourchette du Jour
2,60 € 2,67 €
Fourchette 52 Semaines
1,60 € 3,43 €
Volume
796 468
Moyenne 50J / 200J
2,61 € / 2,46 €
Clôture Précédente
2,58 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique Action Médiane du Secteur
P/E -106,7 0,2
P/B 0,9 3,0
ROE % -0,9 3,6
Net Margin % -4,9 3,8
Rev Growth 5Y % 31,6 9,7
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
2,30 € -12.2%
P/E Prévisionnel
34,93
BPA Prévisionnel
0,08 €
Croissance BPA (est.)
+0,0%
CA Est.
186,17M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2029 0,15 €
0,15 € – 0,15 €
162,47M 1
FY2028 0,14 €
0,14 € – 0,14 €
202,82M 1
FY2027 0,09 €
0,04 € – 0,14 €
207,85M 2

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-26 0,02 € 0,00 € -128,3%
2025-11-06 0,02 € 0,07 € +250,0%
2025-08-07 -0,02 € -0,10 € -400,0%
2025-05-08 -0,01 € 0,02 € +378,6%
2025-02-27 -0,01 € -0,01 € 0,0%
2024-11-12 -0,01 € -0,02 € -300,0%
2024-08-08 0,00 € -0,02 € -700,0%
2024-05-09 -0,01 € -0,01 € -25,0%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 31,55% annually over 5 years — strong growth
Earnings declined -123,00% over the past year
Debt/Equity of 0,00 — conservative balance sheet
Generating 151 611,0 in free cash flow
PEG of 0,88 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 32,85%

Croissance

Revenue Growth (5Y)
31,55%
Revenue (1Y)64,40%
Earnings (1Y)-123,00%
FCF Growth (3Y)N/A

Qualité

Return on Equity
-0,88%
ROIC-0,20%
Net Margin-4,89%
Op. Margin-1,51%

Sécurité

Debt / Equity
0,00
Current Ratio19,59
Interest Coverage0,00

Valorisation

P/E Ratio
-106,67
Forward P/E34,93
P/B Ratio0,92
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 64,40% Revenue Growth (3Y) 48,88%
Earnings Growth (1Y) -123,00% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 31,55% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 193,36M Net Income (TTM) -9,45M
ROE -0,88% ROA -0,79%
Gross Margin 32,46% Operating Margin -1,51%
Net Margin -4,89% Free Cash Flow (TTM) 151 611,0
ROIC -0,20% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 19,59
Interest Coverage 0,00
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -106,67 Forward P/E 34,93
P/B Ratio 0,92 P/S Ratio 5,21
PEG Ratio 0,88 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 5,41 Fwd Earnings Yield 2,86%
FCF Yield 0,02%
Market Cap 1,01B Enterprise Value 217,42M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 193,36M 117,62M 87,24M 86,75M 64,56M
Net Income -9,45M 41,08M -73,96M -168,73M -396,11M
EPS (Diluted) -0,02 0,11 -0,19 -0,45 -1,07
Gross Profit 62,76M 25,20M 11,91M 15,44M -17,59M
Operating Income -2,93M -76,53M -84,80M -111,43M -291,97M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,20B 1,17B 1,14B 1,21B 1,40B
Total Liabilities 54,18M 55,33M 44,14M 72,05M 63,46M
Shareholders' Equity 1,09B 1,06B 1,10B 1,14B 1,34B
Total Debt 1,51M 2,02M 2,55M 3,88M 9,81M
Cash & Equivalents 791,79M 858,81M 669,29M 764,64M 886,97M
Current Assets 944,09M 936,11M 933,31M 960,16M 1,08B
Current Liabilities 48,19M 49,70M 41,40M 68,12M 54,37M

Scores de Stratégies

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#14 of 148
69

Activité Récente

Entré Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré Full Throttle
Mar 24, 2026